Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.82 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.82 |
| ▸ | RAF1 | P04049 | 2/20 | 0.82 |
| ▸ | KDR | P35968 | 2/20 | 0.82 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.82 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.82 |
| ▸ | NEK2 | P51955 | 2/20 | 0.82 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.82 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.82 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.82 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.82 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 0.82 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.82 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.82 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.82 |
| ▸ | PLK4 | O00444 | 1/20 | 0.82 |
| ▸ | PIR | O00625 | 1/20 | 0.82 |
| ▸ | AURKA | O14965 | 1/20 | 0.82 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.82 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29796757 | 1.00 | BRAF (0.82) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL299371 | 0.95 | BRAF (0.73) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL7869149 | 0.94 | BRAF (0.71) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298054 | 0.91 | BRAF (0.73) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL16066437 | 0.91 | BRAF (0.68) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL299440 | 0.91 | BRAF (0.73) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298282 | 0.91 | BRAF (0.84) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL20294639 | 0.90 | BRAF (0.67) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298349 | 0.90 | BRAF (0.83) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL299672 | 0.90 | BRAF (0.83) | BRAFRIPK2RAF1KDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893612-B1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC (US) | 2011-08-03 | — | — | EP | claimed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | claimed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-112424201-B | Protein kinase inhibitors that promote liver regeneration or reduce or prevent hepatocyte death | 海帕瑞吉尼克斯股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129567-A1 | PYRROLO [2, 3. B] PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | BRAF 95/4885RIPK2 477/4885RAF1 36/4885 |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAPK7, MAPK14 | BRAF 64/4885RIPK2 80/4885RAF1 57/4885 |
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | BRAF 1/4885RIPK2 3359/4885RAF1 4/4885 |
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | BRAF 1/4885RIPK2 1855/4885RAF1 3/4885 |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, ARAF, RAF1 | BRAF 1/4885RIPK2 1064/4885RAF1 3/4885 |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | BRAF 48/4885RIPK2 514/4885RAF1 78/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | BRAF 4/4885RIPK2 974/4885RAF1 6/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | BRAF 8/4885RIPK2 1749/4885RAF1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.